WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: Downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice

Oncoscience

Volumn 1, Issue 12, 2014, Pages 807-820

  Fukumoto, Chonji ^a   Nakashima, Dai ^a   Kasamatsu, Atsushi ^b   Unozawa, Motoharu ^a   Shida Sakazume, Tomomi ^a   Higo, Morihiro ^b   Ogawara, Katsunori ^b   Yokoe, Hidetaka ^c   Shiiba, Masashi ^a   Tanzawa, Hideki ^a,b   Uzawa, Katsuhiro ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

Cell cycle; Oral squamous cell carcinoma; PTEN PI3K AKT pathway; Tumoral growth; WWP2

Indexed keywords

EID: 84932638495     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.101     Document Type: Article

References (63)

1. Baba T, Sakamoto Y, Kasamatsu A, Minakawa Y, Yokota S, Higo M, Yokoe H, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Persephin: A potential key component in human oral cancer progression through the RET receptor tyrosine kinase-mitogen-activated protein kinase signaling pathway. Molecular carcinogenesis. 2013.
2. Ishige S, Kasamatsu A, Ogoshi K, Saito Y, Usukura K, Yokoe H, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Decreased expression of kallikrein-related peptidase 13: possible contribution to metastasis of human oral cancer. Molecular carcinogenesis. 2014; 53(7):557-565.
3. Kimura R, Kasamatsu A, Koyama T, Fukumoto C, Kouzu Y, Higo M, Endo-Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Glutamate acid decarboxylase 1 promotes metastasis of human oral cancer by beta-catenin translocation and MMP7 activation. BMC cancer. 2013; 13:555.
4. Shimizu T, Kasamatsu A, Yamamoto A, Koike K, Ishige S, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PloS one. 2012; 7(9):e45510.
5. Uzawa K, Baba T, Uchida F, Yamatoji M, Kasamatsu A, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H and Tanzawa H. Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma. Oncotarget. 2012; 3(7):670-677.
6. Uzawa K, Kasamatsu A, Baba T, Usukura K, Saito Y, Sakuma K, Iyoda M, Sakamoto Y, Ogawara K, Shiiba M and Tanzawa H. Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. Cancer medicine. 2013; 2(1):40-49.
7. Uzawa K, Kasamatsu A, Shimizu T, Saito Y, Baba T, Sakuma K, Fushimi K, Sakamoto Y, Ogawara K, Shiiba M and Tanzawa H. Suppression of metastasis by mirtazapine via restoration of the Lin-7C/beta-catenin pathway in human cancer cells. Scientific reports. 2014; 4:5433.
8. Auld KL and Silver PA. Transcriptional regulation by the proteasome as a mechanism for cellular protein homeostasis. Cell cycle (Georgetown, Tex). 2006; 5(14):1503-1505.
9. Dantuma NP and Masucci MG. Stabilization signals: a novel regulatory mechanism in the ubiquitin/proteasome system. FEBS letters. 2002; 529(1):22-26.
10. Vucic D, Dixit VM and Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nature reviews Molecular cell biology. 2011; 12(7):439-452.
11. Yang Y, Kitagaki J, Wang H, Hou DX and Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer science. 2009; 100(1):24-28.
12. Bassermann F, Eichner R and Pagano M. The ubiquitin proteasome system-implications for cell cycle control and the targeted treatment of cancer. Biochimica et biophysica acta. 2014; 1843(1):150-162.
13. Satija YK, Bhardwaj A and Das S. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. International journal of cancer Journal international du cancer. 2013; 133(12):2759-2768.
14. Chen A, Gao B, Zhang J, McEwen T, Ye SQ, Zhang D and Fang D. The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Molecular and cellular biology. 2009; 29(19):5348-5356.
15. Flores SY, Debonneville C and Staub O. The role of Nedd4/Nedd4-like dependant ubiquitylation in epithelial transport processes. Pflugers Archiv: European journal of physiology. 2003; 446(3):334-338.
16. Li H, Zhang Z, Wang B, Zhang J, Zhao Y and Jin Y. Wwp2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells. Molecular and cellular biology. 2007; 27(15):5296-5305.
17. McDonald FJ, Western AH, McNeil JD, Thomas BC, Olson DR and Snyder PM. Ubiquitin-protein ligase WWP2 binds to and downregulates the epithelial Na(+) channel. American journal of physiology Renal physiology. 2002; 283(3):F431-436.
18. Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM and Jin Y. Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. The Journal of biological chemistry. 2004; 279(22):23495-23503.
19. Zou W, Chen X, Shim JH, Huang Z, Brady N, Hu D, Drapp R, Sigrist K, Glimcher LH and Jones D. The E3 ubiquitin ligase Wwp2 regulates craniofacial development through mono-ubiquitylation of Goosecoid. Nature cell biology. 2011; 13(1):59-65.
20. Chantry A. WWP2 ubiquitin ligase and its isoforms: new biological insight and promising disease targets. Cell cycle (Georgetown, Tex). 2011; 10(15):2437-2439.
21. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN and Chen J. WWP2 is an E3 ubiquitin ligase for PTEN. Nature cell biology. 2011; 13(6):728-733.
22. Soond SM, Smith PG, Wahl L, Swingler TE, Clark IM, Hemmings AM, Chantry A. Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer. Biochim Biophys Acta. 2013; 1832(12):2127-2135.
23. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM and Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer medicine. 2013; 2(4):496-506.
24. Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, Ingolia N and MacPherson D. PTEN is a potent suppressor of small cell lung cancer. Molecular cancer research: MCR. 2014; 12(5):654-659.
25. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, Rutegard J and Palmqvist R. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. British journal of cancer. 2013; 108(10):2153-2163.
26. Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE and Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(24):6830-6841.
27. Rahmani A, Alzohairy M, Babiker AY, Rizvi MA and Elkarimahmad HG. Clinicopathological significance of PTEN and bcl2 expressions in oral squamous cell carcinoma. International journal of clinical and experimental pathology. 2012; 5(9):965-971.
28. Kurasawa Y, Shiiba M, Nakamura M, Fushimi K, Ishigami T, Bukawa H, Yokoe H, Uzawa K and Tanzawa H. PTEN expression and methylation status in oral squamous cell carcinoma. Oncology reports. 2008; 19(6):1429-1434.
29. Assinder SJ, Dong Q, Kovacevic Z and Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. The Biochemical journal. 2009; 417(2):411-421.
30. Carracedo A and Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008; 27(41):5527-5541.
31. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5(13):4603-4650.
32. Yun F, Jia Y, Li X, Yuan L, Sun Q, Yu H, Shi L and Yuan H. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer. International journal of clinical and experimental pathology. 2013; 6(10):2112-2120.
33. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H and Tanzawa H. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. British journal of cancer. 2006; 94(5):717-723.
34. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer research. 1999; 59(22):5724-5731.
35. Minakawa Y, Kasamatsu A, Koike H, Higo M, Nakashima D, Kouzu Y, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Kinesin family member 4A: a potential predictor for progression of human oral cancer. PloS one. 2013; 8(12):e85951.
36. Sakuma K, Kasamatsu A, Yamatoji M, Yamano Y, Fushimi K, Iyoda M, Ogoshi K, Shinozuka K, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. Journal of cancer research and clinical oncology. 2010; 136(4):553-559.
37. Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, Bukawa H, Yokoe H, Seki N and Tanzawa H. Aberrant expression of RAB1A in human tongue cancer. British journal of cancer. 2005; 92(10):1915-1921.
38. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Dermatopontin: a potential predictor for metastasis of human oral cancer. International journal of cancer Journal international du cancer. 2012; 130(12):2903-2911.
39. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, et al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Molecular cell. 2013; 51(4):409-422.
40. Fang L, Wang H, Zhou L and Yu D. Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy. Oral oncology. 2011; 47(1):16-21.
41. Koseoglu S, Lu Z, Kumar C, Kirschmeier P and Zou J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer biology & therapy. 2007; 6(5):755-762.
42. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB and Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral oncology. 2006; 42(4):430-439.
43. Zhang X, Tang N, Hadden TJ and Rishi AK. Akt, FoxO and regulation of apoptosis. Biochimica et biophysica acta. 2011; 1813(11):1978-1986.
44. Sherr CJ and Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & development. 1999; 13(12):1501-1512.
45. Yue H and Jiang HY. Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study. World journal of gastroenterology: WJG. 2005; 11(32):5057-5060.
46. Musgrove EA, Lee CS, Buckley MF and Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(17):8022-8026.
47. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M and Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer research. 2002; 62(11):3200-3206.
48. Tam SW, Theodoras AM, Shay JW, Draetta GF and Pagano M. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene. 1994; 9(9):2663-2674.
49. Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH, Kim JG and Kim CH. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression-transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Glycobiology. 2006; 16(7):573-583.
50. Zhang S, Cheng B, Li H, Xu W, Zhai B, Pan S, Wang L, Liu M and Sun X. Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway. Molecular biology reports. 2014; 41(4):2101-2108.
51. Endo Y, Uzawa K, Mochida Y, Shiiba M, Bukawa H, Yokoe H and Tanzawa H. Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. International journal of cancer Journal international du cancer. 2004; 110(2):225-231.
52. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, Yokoe H and Tanzawa H. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. International journal of molecular medicine. 2005; 16(2):269-273.
53. Koike K, Kasamatsu A, Iyoda M, Saito Y, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Tanzawa H and Uzawa K. High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer. International journal of oncology. 2013; 42(1):141-150.
54. Saito Y, Kasamatsu A, Yamamoto A, Shimizu T, Yokoe H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. ALY as a potential contributor to metastasis in human oral squamous cell carcinoma. Journal of cancer research and clinical oncology. 2013; 139(4):585-594.
55. Shiiba M, Saito K, Fushimi K, Ishigami T, Shinozuka K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A, Sakamoto Y, Ogawara K, Uzawa K, Takiguchi Y and Tanzawa H. Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. International journal of oncology. 2013; 42(4):1197-1204.
56. Shimizu F, Shiiba M, Ogawara K, Kimura R, Minakawa Y, Baba T, Yokota S, Nakashima D, Higo M, Kasamatsu A, Sakamoto Y, Tanzawa H and Uzawa K. Overexpression of LIM and SH3 Protein 1 leading to accelerated G2/M phase transition contributes to enhanced tumourigenesis in oral cancer. PloS one. 2013; 8(12):e83187.
57. Usukura K, Kasamatsu A, Okamoto A, Kouzu Y, Higo M, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Tripeptidyl peptidase II in human oral squamous cell carcinoma. Journal of cancer research and clinical oncology. 2013; 139(1):123-130.
58. Yamamoto A, Kasamatsu A, Ishige S, Koike K, Saito K, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K. Exocyst complex component Sec8: a presumed component in the progression of human oral squamous-cell carcinoma by secretion of matrix metalloproteinases. Journal of cancer research and clinical oncology. 2013; 139(4):533-542.
59. Pindborg JJ and Wahi PN. (1997). Histological typing of cancer and precancer of the oral mucosa: Springer).
60. Sobin LH, Gospodarowicz MK and Wittekind C. (2009). TNM Classification of Malignant Tumours: Wiley).
61. Diaz-Rodriguez E, Alvarez-Fernandez S, Chen X, Paiva B, Lopez-Perez R, Garcia-Hernandez JL, San Miguel JF and Pandiella A. Deficient spindle assembly checkpoint in multiple myeloma. PloS one. 2011; 6(11):e27583.
62. Ferrero M, Ferragud J, Orlando L, Valero L, Sanchez del Pino M, Farras R and Font de Mora J. Phosphorylation of AIB1 at mitosis is regulated by CDK1/CYCLIN B. PloS one. 2011; 6(12):e28602.
63. Verburg FA, Waschle K, Reiners C, Giovanella L and Lentjes EG. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Hormone and metabolic research = Hormon-und Stoffwechselforschung = Hormones et metabolisme. 2010; 42(10):736-739.